Genmab Statistics

Total Valuation

Genmab has a market cap or net worth of $18.08 billion. The enterprise value is $13.91 billion.

Market Cap	18.08B
Enterprise Value	13.91B

Important Dates

The next estimated earnings date is Thursday, August 1, 2024.

Earnings Date	Aug 1, 2024
Ex-Dividend Date	n/a

Share Statistics

Genmab has 651.55 million shares outstanding.

Shares Outstanding	651.55M
Owned by Insiders (%)	0.01%
Owned by Institutions (%)	7.52%
Float	n/a

Valuation Ratios

The trailing PE ratio is 22.75 and the forward PE ratio is 26.04. Genmab's PEG ratio is 1.27.

PE Ratio	22.75
Forward PE	26.04
PS Ratio	7.03
Forward PS	0.85
PB Ratio	3.81
P/FCF Ratio	23.14
PEG Ratio	1.27

Financial Ratio History

Enterprise Valuation

EV / Earnings	17.64
EV / Sales	5.41
EV / EBITDA	n/a
EV / EBIT	11.84
EV / FCF	17.80

Financial Position

The company has a current ratio of 12.46, with a Debt / Equity ratio of 0.03.

Current Ratio	12.46
Quick Ratio	12.44
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	0.19
Interest Coverage	8.12

Financial Efficiency

Return on equity (ROE) is 17.60% and return on invested capital (ROIC) is 13.09%.

Return on Equity (ROE)	17.60%
Return on Assets (ROA)	15.70%
Return on Capital (ROIC)	13.09%
Revenue Per Employee	$1.17M
Profits Per Employee	$357,920
Employee Count	2,204
Asset Turnover	0.51
Inventory Turnover	n/a

Taxes

In the past 12 months, Genmab has paid $235.71 million in taxes.

Income Tax	235.71M
Effective Tax Rate	23.01%

Stock Price Statistics

The stock price has decreased by -32.15% in the last 52 weeks. The beta is 0.83, so Genmab's price volatility has been lower than the market average.

Beta (5Y)	0.83
52-Week Price Change	-32.15%
50-Day Moving Average	27.35
200-Day Moving Average	29.44
Relative Strength Index (RSI)	63.09
Average Volume (20 Days)	617,079

Short Selling Information

Short Interest	2.30M
Short Previous Month	2.51M
Short % of Shares Out	0.17%
Short % of Float	n/a
Short Ratio (days to cover)	5.75

Income Statement

In the last 12 months, Genmab had revenue of $2.57 billion and earned $788.86 million in profits. Earnings per share was $1.21.

Revenue	2.57B
Gross Profit	2.53B
Operating Income	829.21M
Pretax Income	1.03B
Net Income	788.86M
EBITDA	n/a
EBIT	1.18B
Earnings Per Share (EPS)	$1.21

Full Income Statement

Balance Sheet

The company has $4.32 billion in cash and $147.32 million in debt, giving a net cash position of $4.17 billion or $6.40 per share.

Cash & Cash Equivalents	4.32B
Total Debt	147.32M
Net Cash	4.17B
Net Cash Per Share	$6.40
Equity (Book Value)	4.74B
Book Value Per Share	7.27
Working Capital	4.61B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $825.27 million and capital expenditures -$43.76 million, giving a free cash flow of $781.52 million.

Operating Cash Flow	825.27M
Capital Expenditures	-43.76M
Free Cash Flow	781.52M
FCF Per Share	$1.18

Full Cash Flow Statement

Margins

Gross margin is 98.46%, with operating and profit margins of 32.26% and 30.69%.

Gross Margin	98.46%
Operating Margin	32.26%
Pretax Margin	40.10%
Profit Margin	30.69%
EBITDA Margin	n/a
EBIT Margin	45.73%
FCF Margin	30.40%

Dividends & Yields

Genmab does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.17%
Shareholder Yield	-0.17%
Earnings Yield	4.36%
FCF Yield	4.32%

Dividend Details

Analyst Forecast

The average price target for Genmab is $46.00, which is 65.77% higher than the current price. The consensus rating is "Buy".

Price Target	$46.00
Price Target Difference	65.77%
Analyst Consensus	Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	17.83%
EPS Growth Forecast (5Y)	95.98%

Stock Forecasts

Stock Splits

The last stock split was on May 1, 2018. It was a forward split with a ratio of 5:1.

Last Split Date	May 1, 2018
Split Type	Forward
Split Ratio	5:1

Scores

Genmab has an Altman Z-Score of 20.78 and a Piotroski F-Score of 6.

Altman Z-Score	20.78
Piotroski F-Score	6